SEMA3A and benign neoplasm: A high expression of PLXNA2 has been associated with invasive breast ductal carcinoma compared to benign tumours [85], while in ECs, the co-receptor acts as an antiangiogenic and pro-permeability factor through semaphorin 3A signalling.